英诺特: 关于使用部分节余募集资金用于其他募投项目及募投项目延期的公告

Core Viewpoint - The company has decided to utilize part of the remaining raised funds for other investment projects and to extend the timeline for the "in vitro diagnostic product R&D project" by 18 months, from October 2025 to April 2027 [1][3][9]. Fundraising Overview - The company raised a total of RMB 886.56 million (approximately USD 126.5 million) through its initial public offering, with a net amount of RMB 800.48 million (approximately USD 115.5 million) after deducting issuance costs [1][2]. - The funds are managed in a dedicated account as per regulations, and the company has signed a storage supervision agreement with the sponsor and the bank [2]. Investment Project Adjustments - Due to the net amount raised being lower than initially planned, the company adjusted the investment amounts for various projects to ensure efficient use of funds [2]. - The company plans to invest RMB 60 million (approximately USD 8.6 million) of the remaining funds into the "in vitro diagnostic product R&D project" [3][5]. Project Timeline Extension - The timeline for the "in vitro diagnostic product R&D project" has been extended by 18 months, now set to reach a usable state by April 2027 [3][9]. - This project includes research and development of new products and foundational technology for various diagnostic platforms [9]. Strategic Focus - The company aims to enhance its international market presence, particularly in Southeast Asia, and is accelerating clinical trials and submissions for EU IVDR and US FDA products [5][9]. - A strategic partnership with Quanterix Corporation has been established to introduce advanced single-molecule detection technology, focusing on developing products related to neurological biomarkers [5][9]. Decision-Making Process - The decision to use part of the remaining funds and extend project timelines was approved by the company's board and supervisory committee, and it will be submitted for shareholder approval [10][11]. - The supervisory committee and the sponsor have expressed their agreement with the adjustments, confirming compliance with relevant regulations [11][12].